Exicure, Inc.

Equities

XCUR

US30205M2008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.515 ^USD	-4.68%		-13.81%	-11.25%

Mar. 22	North American Morning Briefing : Stocks Struggle After New Records	DJ
Feb. 29	An unknown buyer agreed to acquire 39.3% stake in Exicure, Inc. from DGP Co.,Ltd. for KRW 6 billion.	CI

Exicure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 05:47 pm EDT

Exicure, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 2.47 million compared to USD 0.079 million a year ago. Net loss was USD 7.47 million compared to USD 14.27 million a year ago. Basic loss per share from continuing operations was USD 1.66 compared to USD 4.86 a year ago.
For the six months, revenue was USD 5.04 million compared to USD 1.08 million a year ago. Net loss was USD 15.82 million compared to USD 26.75 million a year ago. Basic loss per share from continuing operations was USD 3.71 compared to USD 9.12 a year ago.

Latest news about Exicure, Inc.

North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
An unknown buyer agreed to acquire 39.3% stake in Exicure, Inc. from DGP Co.,Ltd. for KRW 6 billion.	Feb. 28	CI
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis	Feb. 05	CI
Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts	Dec. 08	MT
Investors Look Ahead to Economic Indicators as US Futures Trend Lower in Friday's Premarket	Dec. 08	MT
Top Premarket Gainers	Dec. 08	MT
Northwestern University Notifies Exicure, Inc. that it Was Terminating the 2014 License	23-10-06	CI
Exicure, Inc. Appoints Minhee Eom to the Board	23-09-27	CI
Exicure Appoints New CEO, CFO	23-08-23	MT
Exicure, Inc. Announces Executive Changes	23-08-23	CI
Exicure, Inc. Announces Chief Financial Officer Changes	23-08-23	CI
Exicure, Inc. Announces Executive Changes	23-08-23	CI
Exicure Inc Provides Information to Shareholders	23-08-23	CI
North American Morning Briefing : China Trouble Hits Sentiment	23-08-18	DJ
Exicure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
CBI Co Provides Information to Shareholders of Exicure Inc	23-08-08	CI
Exicure, Inc. Announces Resignation of Cheolho Jo from the Board and the Audit Committee	23-08-04	CI
Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-07-14	CI
North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23-06-23	DJ
North American Morning Briefing : Stock Futures -2-	23-06-16	DJ
North American Morning Briefing : Caution Ahead of Fed, Inflation Data to Hold Back Stocks	23-06-09	DJ
North American Morning Briefing : Stock Futures -2-	23-06-02	DJ
Exicure, Inc. Appoints Jung Sang as Chief Financial Officer	23-05-29	CI
Exicure, Inc. Appoints Jung Sang Kim as Chief Executive Officer	23-05-29	CI
Exicure, Inc. Appoints Jung Sang Kim as Class II Director	23-05-29	CI

Chart Exicure, Inc.

Duration

Period

More charts

Company Profile

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EXICURE, INC.	-11.25%	4.45M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.51%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.75%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs

Exicure, Inc.

Equities

XCUR

US30205M2008

Biotechnology & Medical Research

Exicure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

Latest news about Exicure, Inc.

Chart Exicure, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs